Therapeutic effect of Leo 1031, an alkylating corticosteroid ester; in lymphoproliferative disorders. II. Lymphocytic lymphoma.
Leo 1031, a chlorambucil ester of prednisolone, has been administered to 20 patients with generalized lymphocytic lymphoma (LL) fo various histologic types. The average daily dose was 40 mg orally; the treatment was given continuously for 1-17 months (mean 7). Complete remission was obtained in five patients and partial remission in ten. The best results were obtained in patients with a nodular type of LL. Significant leucopenia was induced in two patients; no thrombocytopenia has occurred in any patient. In two patients a cushingoid habitus developed after 8 and 4 months, respectively. Leo 1031 may be of value as the single drug in the treatment of some types of LL. A combination therapy will Leo 1031 and vincristine has been tried in 5 of these patients; in 2 as initial therapy and in 3 later in association with relapse. Further trials to assess the value of Leo 1031 as part of a combination schedule are desirable.
D000328:Adult; D000368:Aged; D001853:Bone Marrow; D002699:Chlorambucil / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004952:Esters; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D010997:Pleural Neoplasms / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use
D004952:Esters; D002699:Chlorambucil; D014750:Vincristine; D011239:Prednisolone